Company Overview of MedImmune, LLC
MedImmune, LLC, a biotechnology company, engages in the research and exploration of products in therapeutic areas, including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic diseases; oncology; neuroscience; and infection and vaccines. The company products include Synagis (palivizumab), a monoclonal antibody to prevent lower respiratory tract disease caused by respiratory syncytial virus in children; FluMist Quadrivalent, an influenza vaccine for protection against influenza A and B; and Trivalent FluMist, a nasally-administered live attenuated influenza vaccine. It serves customers globally. The company was formerly known as Molecular Vaccines, Inc. and changed its ...
One MedImmune Way
Gaithersburg, MD 20878
Founded in 1988
Key Executives for MedImmune, LLC
Executive Vice President of Legal Affairs
Senior Vice President of Biopharmaceutical Development
Vice President and Head of Medical & Scientific Affairs - Infectious Disease
Compensation as of Fiscal Year 2014.
MedImmune, LLC Key Developments
Advaxis, Inc. and MedImmune Collaborate on Immuno-Oncology Combination Clinical Trial
Jul 22 14
Advaxis, Inc. entered into a clinical trial collaboration with MedImmune. The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer. Both MEDI4736 and ADXS-HPV are cancer immunotherapies, a new class of treatments that use the body's own immune system to help fight cancer. MEDI4736 is designed to counter the tumour's immune-evading tactics by blocking a signal that helps tumours avoid detection, while ADXS-HPV enhances the ability of immune cells to combat the tumour. Preclinical evidence suggests that the combination of ADXS-HPV with a checkpoint inhibitor, such as MEDI4736, can enhance overall anti-tumour response. Under the terms of the agreement, MedImmune and Advaxis will evaluate the combination as a treatment for HPV-associated cervical cancer and squamous cell carcinoma of the head and neck. The Phase I part of the trial is expected to establish a recommended dose regimen of MEDI4736 with ADXS-HPV, and the Phase II portion will assess the safety and efficacy of the combination. The study will be funded and conducted by Advaxis. Results from the study will be used to determine whether further clinical development of this combination is warranted.
MedImmune, LLC Initiates Phase I Clinical Studies with MEDI8897
Jul 2 14
AIMM Therapeutics announced that its partner MedImmune, LLC has initiated phase I clinical studies with MEDI8897, a best-in-class antibody for the treatment of respiratory syncytial virus (RSV) infections in young, at risk children. MEDI8897 originated from AIMM's D25 antibody. Under the terms of their partnering agreement, AIMM will receive a non-disclosed milestone payment from MedImmune. D25 was developed from immortalized B cells of an individual exposed to RSV utilizing AIMM's proprietary antibody technology platform. Preclinical studies have shown that D25 neutralizes RSV with high efficiency by recognizing a unique epitope on the prefusion structure of the F protein expressed on the virus coat.
ADC Therapeutics and MedImmune Announces Update on Joint Venture
May 18 14
ADC Therapeutics announced that it has selected its first IND candidate under its joint development agreement with MedImmune. This follows the October 2013 announcement in which MedImmune entered into a collaboration agreement with ADC Therapeutics to jointly develop two of ADCT's antibody-drug conjugate programs in preclinical development. ADCT-401 targets Prostate-Specific Membrane Antigen (PSMA) a cell-surface antigen specifically expressed by prostate cancer cells. ADCT-401 comprises an anti-PSMA monoclonal antibody coupled with a pyrrolobenzodiazepine (PBD) warhead using a proprietary linker licensed from London-based Spirogen, a wholly owned subsidiary of MedImmune. Initial clinical studies will focus on hormone-refractory prostate cancer and an IND filing is anticipated in 2015. The PSMA-specific J591 antibody in ADCT-401 was developed by Dr. Neil H. Bander, the Bernard & Josephine Chaus Professor of Urologic Oncology and Director of Urological Oncology Research at the Weill-Cornell Medical College, New York. Dr. Bander is also Chairman of ADCT's Scientific Advisory Board. PSMA is a cell-surface antigen expressed by virtually all prostate cancer cells, including metastases, and also in the blood vessels that feed many other tumor types, but is rarely expressed in normal cells. This will be ADCT's second ADC program into the clinic from its pipeline of eleven programs with an IND filing expected in the first of these programs by the end of the year 2014. The pre-clinical development of ADCT-401 is being managed by a team of scientists based in laboratories at the Queen Mary Bioenterprises Innovation Centre, London which, being co-located with Spirogen, enables close co-operation between the two groups.
Similar Private Companies By Industry
Recent Private Companies Transactions